SHAREHOLDER ALERT:  Brodsky & Smith, LLC Announces an Investigation of Kite Pharma, Inc. – KITE

 

BALA CYNWYD, August 28, 2017 /Access Wire/ – Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Kite Pharma, Inc. (“Kite” or “the Company”) (Nasdaq- KITE-News) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Gilead Sciences, Inc. (“Gilead”).

Under the terms of the transaction, Kite shareholders will receive only $180.00 in cash for each share of Kite stock they own. The investigation concerns whether the Board of  Kite breached their fiduciary duties to shareholders and whether Gilead is underpaying for the Company. The transaction may undervalue the Company as Kite’s leading CAR-T agent commonly known as axi-cel ia awaiting FDA approval, with a decision due by November 29, 2017. Consequently, an analyst has indicated that by 2025 Kite’s CAR-T inhibitors could generate global sales of $5 billion.

If you own shares of Kite stock and wish to discuss the legal ramifications of  the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA  19004, or calling toll free 877-LEGAL-90.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.